卵巢癌抗血管靶向治疗临床研究进展

被引：16

作者：

胡元晶 ^{[1
]}

薛凤霞 ^{[2
]}

机构：

[1] 天津市中心妇产科医院

[2] 天津医科大学总医院

来源：

国际妇产科学杂志 | 2010年 / 37卷 / 04期

关键词：

卵巢肿瘤; 血管内皮生长因子类; 治疗; 临床试验;

D O I：

暂无

中图分类号：

R737.31 [卵巢肿瘤];

学科分类号：

100214 [肿瘤学];

摘要：

靶向治疗是针对肿瘤组织有别于正常组织的特征,给予有针对性的治疗,从而达到较好治疗效果和较小的不良反应。目前抗肿瘤靶向治疗研究中最多的是抗血管治疗,不断研发出许多新的药物,并已广泛用于临床试验。对近年来卵巢癌抗血管靶向治疗的临床研究加以综述,以介绍这一新治疗方法在卵巢癌中的治疗现状、面临问题和前景。

引用

页码：271 / 273+293 +293

页数：4

共 8 条

[1]

Sustained progression-free survival with weekly paclitaxel and bevacizumab in recurrent ovarian cancer [J].

Hurt, J. D. ;

Richardson, D. L. ;

Seamon, L. G. ;

Fowler, J. F. ;

Copeland, L. J. ;

Cohn, D. E. ;

Eisenhauer, E. ;

Salani, R. ;

O'Malley, D. M. .

GYNECOLOGIC ONCOLOGY, 2009, 115 (03) :396-400

[2]

The risk of gastrointestinal perforation and/or fistula in patients with recurrent ovarian cancer receiving bevacizumab compared to standard chemotherapy: A retrospective cohort study [J].

Sfakianos, Gregory P. ;

Numnum, T. Michael ;

Halverson, Caitlin B. ;

Panjeti, Deepa ;

Kendrick, James E. ;

Straughn, J. Michael, Jr. .

GYNECOLOGIC ONCOLOGY, 2009, 114 (03) :424-426

[3]

Anti-angiogenesis therapy with bevacizumab for patients with ovarian granulosa cell tumors [J].

Tao, Xia ;

Sood, Anil K. ;

Deavers, Michael T. ;

Schmeler, Kathleen M. ;

Nick, Alpa M. ;

Coleman, Robert L. ;

Milojevic, Ljiljana ;

Gershenson, David M. ;

Brown, Jubilee .

GYNECOLOGIC ONCOLOGY, 2009, 114 (03) :431-436

[4]

Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: A trial of the Chicago, PMH, and California Phase II consortia [J].

Nimeiri, Halla S. ;

Oza, Amit M. ;

Morgan, Robert J. ;

Friberg, Gregory ;

Kasza, Kristen ;

Faoro, Leonardo ;

Salgia, Ravi ;

Stadler, Walter M. ;

Vokes, Everett E. ;

Fleming, Gini F. .

GYNECOLOGIC ONCOLOGY, 2008, 110 (01) :49-55

[5]

Circulating cell-free DNA - A novel biomarker for response to therapy in ovarian carcinoma [J].

Kamat, Aparna A. ;

Bischoff, Farideh Z. ;

Dang, Dianne ;

Baldwin, Matthew F. ;

Han, Liz Y. ;

Lin, Yvonne G. ;

Merritt, William M. ;

Landen, Charles N. ;

Lu, Chunhua ;

Gershenson, David M. ;

Simpson, Joe L. ;

Sood, Anil K. .

CANCER BIOLOGY & THERAPY, 2006, 5 (10) :1369-1374

[6]

Safety and efficacy of thalidomide in recurrent epithelial ovarian and peritoneal carcinoma [J].

Chan, John K. ;

Manuel, Michael R. ;

Ciaravino, Giuseppe ;

Cheung, Michael K. ;

Husain, Amreen ;

Teng, Nelson N. H. .

GYNECOLOGIC ONCOLOGY, 2006, 103 (03) :919-923

[7]

Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer [J].

Monk, Bradley J. ;

Han, Ernest ;

Josephs-Cowan, Carol A. ;

Pugmire, Gordon ;

Burger, Robert A. .

GYNECOLOGIC ONCOLOGY, 2006, 102 (02) :140-144

[8]

Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study [J].

Gordon, AN ;

Finkler, N ;

Edwards, RP ;

Garcia, AA ;

Crozier, M ;

Irwin, DH ;

Barrett, E .

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2005, 15 (05) :785-792

← 1 →